Russia’s Space Weapons Put U.S. Spy Satellites in the Crosshairs: Russia appears to be moving from testing to operating anti-satellite weapons in low-Earth orbit, according to Gen. Stephen Whiting, head of U.S. Space Command. The system is believed to be Nivelir, a series of Russian “nesting doll” satellites that can release smaller craft and potentially fire projectiles. Several have been launched into orbital planes that allow them to shadow high-value U.S. National Reconnaissance Office spy satellites. Whiting said the placement shows clear intent, comparing it to testing a fighter jet’s weapons near an adversary’s bomber. The concern is strategic: U.S. military operations depend heavily on satellites for surveillance, navigation, missile warning, and communications. Russia’s weaker conventional position may be pushing it toward asymmetric space, cyber, and nuclear threats. (Ars Technica)

Sperm May Carry More Than DNA: Sperm may do more than deliver a father’s DNA to an egg. A new mouse study suggests they also pick up messenger RNAs while maturing in the epididymis, the coiled tube sperm pass through after leaving the testes. These RNAs appear to be transferred into the fertilized egg, where they may influence early embryonic gene expression. Researchers found that vesicles called epididymosomes can pass mRNAs to sperm, and that some sperm-carried transcripts later appear in zygotes. Experiments with long RNA injections in mouse eggs showed that sperm-like RNA cargo can shift gene activity toward patterns seen in normally fertilized embryos. Human sperm carried similar mRNAs, hinting the mechanism may extend beyond mice, though its true developmental impact remains uncertain. (Science)

FDA Clears Regeneron Gene Therapy for Rare Inherited Deafness: A rare form of congenital deafness now has a gene therapy option. The FDA approved Regeneron’s Otarmeni for children with hearing loss caused by mutations in the OTOF gene, a condition that leaves the ear unable to transmit sound properly despite intact structures. The one-time therapy is designed to deliver a working copy of the gene and, according to BioPharma Dive, becomes the first gene therapy cleared through the FDA’s “national priority” voucher program. The approval matters not only for children with this specific mutation, but also for the broader field of sensory gene therapy, where eye and ear disorders are increasingly seen as tractable targets for localized genetic medicine. (BioPharma Dive)

Lilly Bets Billions on In Vivo CAR-T: Eli Lilly is buying Kelonia Therapeutics for as much as $7 billion, a move that pushes the drugmaker deeper into oncology and genetic medicine. Kelonia is developing CAR-T therapies that aim to engineer immune cells inside the patient’s body rather than removing, modifying, and reinfusing cells in the traditional way. Its lead candidate, KLN-1010, is in early testing for multiple myeloma. The acquisition includes $3.25 billion upfront and milestone payments, and Reuters reports the deal is expected to close in the second half of 2026. The larger implication is strategic: major pharmaceutical companies are increasingly treating in vivo cell engineering as a possible next phase of cancer immunotherapy. (Reuters)

A New Keytruda Booster Draws Big Pharma Attention: Inhibrx Biosciences has reportedly attracted interest from Merck, Merck KGaA, Ono Pharmaceutical, and other major drugmakers for INBRX-106, an experimental cancer antibody being tested with Keytruda. Reuters reports the drug could be valued above $8 billion if clinical data hold up. The attraction is obvious: Keytruda remains one of the world’s most important cancer drugs, but Merck faces looming patent pressure. INBRX-106 is designed to stimulate T-cell activity and may raise response rates in advanced head and neck cancer when paired with Keytruda. The story is still early, but it captures a core biotech theme of 2026: extending immunotherapy’s reach by combining checkpoint blockade with new immune activators. (Reuters)

Modified CRISPR Takes Aim at Down Syndrome’s Extra Chromosome: Researchers are exploring a modified CRISPR strategy to silence the extra copy of chromosome 21 that causes Down syndrome. Labiotech reports that scientists at Beth Israel Deaconess Medical Center and Harvard Medical School used CRISPR with XIST, a long non-coding RNA normally involved in X-chromosome silencing, to target trisomy 21 in human cells and stem cells. The key advance is not simply cutting DNA, but inserting a silencing system with much higher efficiency than standard CRISPR insertion. The work remains preclinical and delivery remains a major barrier, especially for brain cells. Still, the approach is striking because it targets the chromosomal root of the disorder rather than downstream symptoms. (Labiotech.eu)

A Three-Amino-Acid Boost Could Supercharge mRNA Delivery: A simple delivery tweak may make mRNA therapies substantially more powerful. ScienceDaily reports on research from Biohub showing that adding three common amino acids to lipid nanoparticles can increase mRNA delivery up to 20-fold and push CRISPR editing efficiency close to 90% in early tests. The finding is important because delivery remains one of the major bottlenecks in mRNA drugs, gene editing, and many next-generation genetic medicines. Instead of redesigning the therapeutic payload, the strategy helps cells take up the particles more effectively. If it translates beyond early models, this could improve lower-dose treatments, expand mRNA applications beyond vaccines, and make CRISPR therapies more efficient and potentially safer. (ScienceDaily)

AACR 2026 Shows Cancer Therapy Moving Beyond Single Targets: This year’s AACR meeting highlighted how cancer therapeutics are shifting toward combinations, bispecifics, precision subgroups, and immune modulation. Labiotech’s roundup focuses on several data points from the San Diego meeting, including Merck’s MK-2010, a bispecific antibody tested in PD-L1-positive non-small cell lung cancer, and Nuvalent’s zidesamtinib for ROS1-positive lung cancer patients who have exhausted existing kinase inhibitor options. The larger story is not one miracle drug, but a field becoming more layered. Tumors are being divided into smaller molecular niches, resistance mechanisms are being anticipated, and therapies are increasingly designed to work in combinations. The result is a more complicated but more rational cancer pipeline. (Labiotech.eu)

Japan Marks a First for iPSC-Based Therapies: Nature Biotechnology reports that Japan has seen the world’s first two induced pluripotent stem cell therapies move into therapeutic use. The short news item is light on detail without subscription access, but the significance is clear: iPSC technology has long promised patient-compatible or broadly banked replacement cells, yet translation into approved or clinically deployed products has been slow. Japan has been especially active in regenerative medicine regulation and clinical development, making it an important proving ground. The broader biotech question is whether iPSC-derived cells can become a scalable platform for treating degenerative disease, immune disorders, retinal conditions, and tissue damage, rather than remaining isolated experimental successes. (Nature)

Plastic-Eating Fungi Point Toward Environmental Biotech: Disposable diapers are a stubborn waste problem, built from materials that resist easy breakdown. Nature Biotechnology reports on plastic-eating fungi as a potential environmental biotechnology answer. The item, published April 17, frames the research as part of a broader effort to use biological systems to digest or transform difficult waste streams. The appeal is obvious: fungi already specialize in breaking down complex organic matter, and some species can attack synthetic polymers under the right conditions. The challenge is turning laboratory degradation into something fast, safe, and scalable enough for real-world waste handling. Even so, the story shows biotechnology expanding beyond medicine into materials, waste, and circular-economy infrastructure. (Nature)

Resistance Genes Appear in Newborns Within Days: Antibiotic resistance may enter the human microbiome almost immediately after birth. CIDRAP reports that antibiotic-resistance genes were detected in babies within their first three days of life, based on research presented at ESCMID Global 2026. The study is described as the largest of its kind focused on resistance genes in the neonatal gut. This matters because antimicrobial resistance is often discussed as a hospital, agriculture, or adult-treatment problem, but newborn colonization suggests the pipeline can begin much earlier. The findings raise questions about maternal transmission, delivery environments, early antibiotic exposure, neonatal intensive care settings, and the first microbial communities that shape later health. It is a microbiome story with direct public-health consequences. (CIDRAP)

Europe Authorizes Moderna’s Combo Flu-COVID Shot: Moderna’s combination seasonal influenza and COVID-19 vaccine, mCombriax, has received marketing authorization from the European Commission. CIDRAP reports that the shot follows a positive review from the European Medicines Agency’s Committee for Medicinal Products for Human Use and is described as the world’s first combination seasonal flu-COVID vaccine. The product builds on Moderna’s COVID vaccine platform and its investigational seasonal flu vaccine work. Combination vaccines are not just a convenience story; they may help simplify annual vaccination campaigns, reduce missed opportunities, and make respiratory-virus prevention easier for older adults and other high-risk groups. The authorization also shows mRNA vaccine development continuing beyond the emergency phase of the pandemic. (CIDRAP)